Substituted quinazoline compounds useful as p38 kinase inhibitors

A method for treating a p38-mediated disorder in a patient comprising administering to the patient in need of such treatment, an effective amount of a compound having the formula (II):

• or an isomer, prodrug, or pharmaceutically-acceptable salt thereof, wherein:
• Qa is selected from alkyl, substituted alkyl, heteroalkyl, or an optionally-substituted cycloalkyl or heterocyclic ring, provided that Q is not arylalkyl or heteroarylalkyl;
• Y is —O—, —S—, or —NR′—, wherein R′ is hydrogen, lower alkyl, or lower alkyl substituted with OH;
• R is alkyl, substituted alkyl, or optionally-substituted aryl, heteroaryl, cycloalkyl, or heterocyclyl;
• R6 is attached to any available carbon atom of the quinazoline ring and at each occurrence is independently selected from alkyl, substituted alkyl, halogen, cyano, nitro, hydroxy, alkoxy, haloalkoxy, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, and substituted heteroaryl;
• and
• m is 0, 1, 2or 3.